CTRV - ContraVir Pharmaceuticals, Inc.
(NaN%)
We couldn't determine Recommendation based on the data we have.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
ContraVir Pharmaceuticals, Inc. (CTRV) - http://www.contravir.com
ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.Exchange - NASDAQ
Industry - Pharmaceuticals: Other
Sector - Health Technology
CEO - Robert T. Foster
Employees - 14
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.